Health tech seed VCs in 2026: who writes clinical checks vs digital

I watched a medical device founder pitch 34 health tech seed investors over six months. Five passed because they only funded digital therapeutics. Eight more passed because they avoided anything with FDA pathway risk. Three had exited the sector entirely after their 2021 vintage stalled. By the time he found out which firms actually wrote clinical-stage checks, he had burned through half his runway and most of his warm intros.

The list you are working from probably has the same problem. "Health tech" is too broad a category. The firms that back glucose monitoring apps do not write checks for implantable diagnostics. The investors who funded telemedicine platforms in 2020 are not the same ones funding AI radiology models with 510(k) timelines in 2026.

This guide splits the health tech seed investor universe into two groups: clinical-stage investors who will fund hardware, diagnostics, and anything with a regulatory path, and pure digital health investors who stay in software, data platforms, and consumer wellness. The distinction matters because your deck and your traction metrics need to be completely different depending on which group you are pitching.

Why the split matters more in 2026 than it did in 2021

In 2021, nearly every generalist seed fund was willing to look at health tech. Capital was abundant. Health software multiples were sky-high. Regulatory risk felt manageable if the team was good and the TAM was big enough.

By 2024, that changed. Digital health valuations corrected hard. Several high-profile telemedicine exits disappointed. FDA timelines stretched longer than expected for AI diagnostic tools. Meanwhile, GLP-1 drugs reshaped the obesity and diabetes software markets overnight, killing traction for companies that had spent two years building around the old standard of care.

Now, in 2026, the health tech seed market has sorted itself. Some firms doubled down on clinical bets, writing bigger checks into fewer companies with real IP and long timelines. Others retreated to pure software plays, where you can show revenue in six months and avoid any interaction with the FDA. A third group exited health entirely.

If you are raising right now, you need to know which bucket each investor falls into before you send the deck. The firms that say "health tech" on their website are not all playing the same game.

Clinical-stage health tech seed investors: who still writes these checks

Clinical-stage investors are comfortable with FDA pathways, reimbursement timelines, and capital-intensive R&D. They expect longer development cycles and are not looking for SaaS-style ARR growth in year one. They care about IP, clinical validation, and team pedigree (especially regulatory and clinical ops experience).

These firms write seed checks into medical devices, diagnostics, bioelectronics, drug delivery platforms, and AI tools that require 510(k) or De Novo clearance.

Firms with consistent clinical-stage mandates

Canaan Partners has been writing health tech seed checks for more than a decade. Their portfolio includes companies with FDA pathways, and they have dedicated partners with clinical backgrounds. They are not allergic to hardware, and they understand reimbursement timelines.

OrbiMed writes early checks into biopharma, devices, and diagnostics. They have the capital base to support multi-year clinical development, and they do not panic when milestones shift by quarters instead of weeks.

Khosla Ventures backs moonshots, including clinical-stage companies with long timelines. They wrote early checks into companies working on AI diagnostics, wearable sensors, and implantable devices. If your clinical bet has real scientific novelty, they will hear the pitch.

ARCH Venture Partners is known for tough science bets. They have funded companies working on implantable bioelectronics, gene therapy delivery, and closed-loop neuromodulation. They expect clinical data, but they do not expect revenue in year one.

Casdin Capital focuses on life sciences and biopharma, but they write seed and Series A checks into health tech companies with strong clinical or therapeutic angles. If your product intersects with drug development, diagnostics, or precision medicine, they are a real option.

What clinical-stage investors want to see in your deck

They do not want to see a TAM slide that treats "healthcare" as a single addressable market. They want to see which indication you are targeting, what the reimbursement pathway looks like, and who the clinical champions are.

They care about:

• Clinical validation. Pilot data, physician feedback, early feasibility study results. Not user surveys.
• Regulatory strategy. Which FDA pathway? How long? What are the predicate devices? Have you talked to the agency?
• IP position. What is patented, what is trade secret, and who else is working in this space?
• Team depth in regulatory and clinical ops. If your founding team has never filed a 510(k) or run a clinical trial, they want to see advisors or hires who have.

Revenue is nice, but it is not the main signal. Clinical-stage investors are buying risk, not traction. If your deck leads with ARR and buries the FDA timeline, you are positioning wrong for this group.

If you need help structuring a deck for clinical investors, the narrative arc guide has a section on how to frame regulatory risk without spooking the room.

Pure digital health seed investors: who stays in software

Pure digital health investors avoid hardware, avoid FDA pathways, and stay firmly in software, data platforms, and consumer wellness. They expect faster timelines, clearer revenue models, and less dependency on clinical reimbursement.

These firms write seed checks into telemedicine platforms, patient engagement tools, care coordination software, wellness apps, health data infrastructure, and AI tools that do not require FDA clearance (clinical decision support, administrative automation, population health analytics).

Firms with digital-first health mandates

Rock Health is the most explicit digital health seed investor. They fund software-first companies and avoid anything with a long regulatory path. If your product is a consumer health app, a B2B SaaS tool for payers or providers, or a data platform, they are a strong fit.

Andreessen Horowitz (a16z Bio + Health) has two tracks. The Bio fund writes clinical bets. The core health practice writes checks into digital health software, especially marketplace models and workflow automation for clinicians. Make sure you are pitching the right partner.

General Catalyst has a dedicated health team that writes seed and Series A checks into digital health software. They funded companies working on care navigation, benefits administration, and EHR workflow tools. They are comfortable with B2B2C models and long sales cycles, but they avoid hardware and FDA risk.

Thrive Capital has backed consumer health companies with strong digital models. They do not write clinical checks, but they will fund a direct-to-consumer wellness company with real retention and a path to profitability.

FirstMark Capital writes health software checks, particularly into tools that serve clinicians or health systems. They are not deep in biopharma or devices, but they understand SaaS economics in healthcare.

What digital health investors want to see in your deck

They want to see revenue, growth rate, and a clear path to profitability. They care about customer acquisition cost, retention, and unit economics. They do not care about clinical validation unless it drives conversion or willingness to pay.

They care about:

• Revenue or signed pilots. If you have no revenue at seed, you need real LOIs or signed pilots with named health systems or payers.
• Market timing. Why now? What regulatory or reimbursement change makes this possible today and not three years ago?
• Go-to-market clarity. Are you selling to patients, providers, payers, or employers? What does the sales cycle look like?
• Unit economics. What does it cost to acquire a user or customer? How long until payback?

Clinical validation is fine, but it is not the core signal. Digital health investors are buying growth, not science. If your deck spends three slides on your clinical advisory board and zero slides on how you are acquiring users, you are positioning wrong for this group.

How to figure out which group an investor belongs to before you pitch

Most health tech investors do not label themselves cleanly. Their website says "health tech" and lists a portfolio that includes both telemedicine software and diagnostic devices. You need to do the research.

Here is how to sort them:

1. Look at the last five health investments they made. Not the portfolio page, the recent activity. If the last five deals were all software, they are a digital investor. If three of the last five had FDA pathways, they write clinical checks.
2. Check the partner bios. Do they have MDs, PhDs, or regulatory experience? That is a signal they write clinical checks. If the partners are all ex-operators from SaaS or consumer tech, they probably stay digital.
3. Look at their fund size and check size. Clinical-stage deals need bigger seed rounds (often $3M to $5M) and longer runways. If the firm writes $500K to $1M seed checks and expects 18-month milestones, they are not set up for clinical timelines.
4. Search for their name plus "FDA" or "510(k)" in news and press releases. If they have never announced a deal involving regulatory approval, they do not write those checks.

If you are not sure after that research, just ask in the intro email. "We are raising a seed round for a Class II diagnostic device with a 510(k) pathway. Is this within your mandate?" You will get a no in 24 hours if it is not, and you save yourself a month of back-and-forth.

For more on how to research investors without relying on outdated databases, see the free investor research guide.

The firms that write both kinds of checks (and how to tell which partner to pitch)

A few large funds have dedicated clinical and digital practices under the same brand. Andreessen Horowitz, General Catalyst, and Lux Capital all write both types of checks, but you need to pitch the right partner.

If you are targeting one of these firms:

• Go to the team page. Find the partner who led deals similar to yours. Do not pitch the general health inbox.
• Reference a specific portfolio company in your intro. "I saw you led the Series A for [Company X], which also has a 510(k) pathway in remote monitoring. We are building something similar in cardiac diagnostics." That gets you routed to the right person.
• Do not assume the entire firm has the same mandate. Just because Andreessen Horowitz funded a diagnostic startup does not mean every health partner at a16z writes clinical checks. Pitch the partner, not the firm.

Cold email vs warm intro: does it matter more in health tech?

Yes. Health tech investors get a higher volume of irrelevant pitches than almost any other vertical. Half the decks they see are from founders who did not check whether the firm writes clinical checks, or whether the firm is even active in health anymore.

That means warm intros matter more in health tech than in, say, vertical SaaS. If you cold email a health tech investor without doing the research first, you are one of 40 unqualified pitches that week. If you get introduced by a founder they backed, or a clinical advisor they know, you skip that pile.

But cold email still works if you do the research. Among the founders I have worked with, cold emails to health tech investors that reference a specific portfolio company, a specific regulatory pathway, or a recent fund announcement convert at about the same rate as warm intros. The key is proving you did the work.

For data on cold email conversion rates by investor type, see the cold email vs warm intro guide.

What to do if you are raising right now and your list is wrong

If you are six weeks into your raise and you are getting a lot of passes that sound like "this is not our mandate" or "we do not do hardware," your list is wrong. Stop pitching and fix the list.

Go back through the last 20 investors you contacted. Sort them into clinical, digital, and unclear. If most of the passes came from digital investors and you are building a clinical-stage company, you just wasted 20 intros.

Rebuild the list using the research steps above. Filter by recent deals, partner background, and check size. Cut any firm that has not written a health tech check in the last 18 months. Cut any firm where the health partner left and has not been replaced.

Then re-prioritize. Pitch the firms that match your category first. Save the generalists and the unclear firms for later in the process, after you have real momentum with the specialists.

If you are not sure which investors match your deck, score your deck at /upload and the tool will surface a filtered list of active investors based on your stage, vertical, and traction type. It takes 30 seconds and it is free. You will know immediately if your list matches your company, or if you have been pitching the wrong group for the last two months.

<<>>